Kronos Bio Email Format

Biotechnology ResearchCalifornia, United States51-200 Employees

Kronos Bio is a clinical-stage biotechnology company focused on developing small-molecule therapeutics that address cancers driven by deregulated transcription. Its lead program KB-0742 is a CDK9 inhibitor in a phase 1/2 trial for MYC-dependent tumors, including triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as other transcriptionally addicted cancers. A second development candidate, KB-9558, targets the KAT domain of p300, a key node in an oncogenic transcription program associated with multiple myeloma. In 2023, Kronos Bio began a discovery collaboration with Genentech to pursue therapies targeting transcriptional regulators in oncology.

Kronos Bio is based in San Mateo, California, and operates as a mid-sized player in the biotechnology research field. During 2025, the company was acquired by Concentra Biosciences, reflecting a significant corporate development while its translational research programs continue.

Sign up for free to view info

Company overview Employee directory